New Alzheimer's medicine of Beijing new pharmaceutical industry is expected to be approved this year

Source: great wisdom astak news agency January 20, 2015, Beijing New Pharmaceutical Co., Ltd (002020 SZ) mentioned in the latest public information that the company's research variety kabaradin is expected to be approved this year Previously, the company said on the interactive platform that the product has a large market capacity According to the information on the website of the State Food and Drug Administration (CFDA), Beijing new pharmaceutical's cabalatine heavy tartrate capsule was applied for acceptance in June 2011, which has lasted for more than three years At present, the domestic market of kabalatin bitartrate is monopolized by Novartis The enterprises in the process of product research and development also include Enhua Pharmaceutical (002262 SZ), Huahai Pharmaceutical (600521 SH), Shanghai Sanwei pharmaceutical, vante pharmaceutical, etc According to the public information, carbalatin bitartrate is an acetylcholinesterase inhibitor, which is the mainstream drug for the treatment of Alzheimer's disease The original manufacturer is Novartis The experimental data showed that kabalatin tartrate was well tolerated to mild and moderate Alzheimer's disease due to no metabolism of liver and P450 (cytochrome) It was highly evaluated in a prospective, randomized, multicenter, double-blind study conducted in 45 countries including Europe and the United States Before Beijing New Pharmaceutical Co., Ltd went public, it mainly engaged in fluoroquinolones as raw materials for anti infective drugs Through many years of operation, it has actively transformed into preparations At present, the gross profit contribution rate of preparation business has exceeded that of raw materials and become the main profit contribution source of the company